Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 12:57:34 - browse：2677

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How a small hospital in rural Puerto Rico survived Hurricane Maria

leisure time

WSS

Childhood cancer progress stalls for Black, Hispanic kids: Report

Gain of function research would be limited under House proposal

Class action alleges UnitedHealth concealed DOJ probe

World's first CRISPR

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Crowdfunding for medical bills sidesteps core problem, author says

hotspot

Wikipedia

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Ransomware attacks on hospitals: Study outlines patient impact

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

The cancer drug shortage isn’t new — and neither are the solutions

Welsh Carson private equity firm escapes from FTC antitrust case

Virginia high school admissions case could be legal follow

BIO to announce reorganization, senior leaders expected to depart

leisure time

Lawmakers grill UnitedHealth CEO on Change cyberattack

Empower primary care with adequate payments and technology

World's first CRISPR

Empower primary care with adequate payments and technology

World's first CRISPR

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Wikipedia

leisure time

focus

knowledge